Results 41 to 50 of about 13,529 (168)

Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis

EBioMedicine, 2016
Neovascular eye diseases including retinopathy of prematurity, diabetic retinopathy and age-related-macular-degeneration are major causes of blindness.
Yan Gong, Zhuo Shao, Zhongjie Fu, Matthew L. Edin, Ye Sun, Raffael G. Liegl, Zhongxiao Wang, Chi-Hsiu Liu, Samuel B. Burnim, Steven S. Meng, Fred B. Lih, John Paul SanGiovanni, Darryl C. Zeldin, Ann Hellström, Lois E.H. Smith   +14 more
doaj   +1 more source

Effects of different levels of fenofibrate on growth performance, carcase characteristics, abdominal fat, serum constitutes, immune system, caeca and microbial flora of broilers

Italian Journal of Animal Science, 2022
So far, the effect of fenofibrate on the performance, quantitative and qualitative characteristics of broilers have not been investigated. For this reason, this study was performed to evaluate the effects of different levels of fenofibrate on the ...
Maryam Azizi, Mehrdad Bouyeh, Alireza Seidavi   +2 more
doaj   +1 more source

SIRT5‐Mediated Desuccinylation of ACAA2 Protects Against Calcium Oxalate‐Induced Kidney Injury by Regulating Fatty Acid Oxidation to Suppress Mitochondrial Oxidative Injury and Ferroptosis

Advanced Science, EarlyView.
The SIRT5/ACAA2 axis maintains lipid metabolic homeostasis in RTECs by promoting ACAA2 desuccinylation and preserving its stability and enzymatic activity, thereby sustaining FAO and limiting PUFA and PUFA‐containing phospholipid accumulation. Under CaOx stress, SIRT5 downregulation impairs FAO, promotes oxidative stress and ferroptosis, and enhances ...
Qinhong Jiang, Caitao Dong, Yuchen Liu, Yuanquan Lou, Wenlong Lin, Sheng Li, Ziqi He   +6 more
wiley   +1 more source

Topical and oral peroxisome proliferator-activated receptor-α agonist ameliorates diabetic corneal neuropathy

Scientific Reports
Diabetic corneal neuropathy (DCN) is a common diabetic ocular complication with limited treatment options. In this study, we investigated the effects of topical and oral fenofibrate, a peroxisome proliferator-activated receptor-α agonist, on the ...
Hassan Mansoor, Isabelle Xin Yu Lee, Molly Tzu-Yu Lin, Heng Pei Ang, Yao Cong Xue, L. Krishaa, Moushmi Patil, Siew-Kwan Koh, Hong Chang Tan, Lei Zhou, Yu-Chi Liu   +10 more
doaj   +1 more source

Small heterodimer partner-targeting therapy inhibits systemic inflammatory responses through mitochondrial uncoupling protein 2. [PDF]

PLoS ONE, 2013
The orphan nuclear receptor, small heterodimer partner (SHP), appears to play a negative regulatory role in innate immune signaling. Emerging evidence warrants further study on the therapeutic targeting of SHP to suppress excessive and deleterious ...
Chul-Su Yang, Jae-Min Yuk, Jwa-Jin Kim, Jung Hwan Hwang, Chul-Ho Lee, Jin-Man Kim, Goo Taeg Oh, Hueng-Sik Choi, Eun-Kyeong Jo   +8 more
doaj   +1 more source

Fenofibrate Administration Reduces Alcohol and Saccharin Intake in Rats: Possible Effects at Peripheral and Central Levels

Frontiers in Behavioral Neuroscience, 2017
We have previously shown that the administration of fenofibrate to high-drinker UChB rats markedly reduces voluntary ethanol intake. Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist, which induces the proliferation of ...
Mario Rivera-Meza, Daniel Muñoz, Erik Jerez, María E. Quintanilla, Catalina Salinas-Luypaert, Katia Fernandez, Eduardo Karahanian, Eduardo Karahanian   +7 more
doaj   +1 more source

Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs. [PDF]

PLoS ONE, 2015
Nephrotoxicity is a major side effect for the antineoplastic drug cisplatin. Here, we employed pharmacological, biochemical, and molecular studies to investigate the role of peroxisome proliferator-activated receptors (PPARs) in cisplatin nephrotoxicity.
Mai M Helmy, Maged W Helmy, Mahmoud M El-Mas   +2 more
doaj   +1 more source

Elevated INR Following Coadministration of Warfarin with Fenofibrate: A Case Report and Review of the Literature

Biomedical Sciences and Clinical Medicine, 2022
Fenofibrate, a lipid lowering drug, can increase the effects of warfarin and may cause bleeding more easily. We report a case of a 58-year-old Thai male patient who was administered warfarin at 27 mg per week to achieve the target international ...
Kanokwan Thitiratamornkit, Sarawuth Limprasert, Pornwalai Boonmuang   +2 more
doaj   +1 more source

Fenofibrate Attenuates Renal Tubular Cell Apoptosis by Up-Regulating MCAD in Diabetic Kidney Disease

Drug Design, Development and Therapy, 2023
Chao Tang,1,2,* Xiaoqing Deng,1,* Jingru Qu,1 Yahui Miao,1 Lei Tian,1 Man Zhang,1 Xiaoyu Li,1 Bei Sun,1 Liming Chen1 1NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital ...
Tang C, Deng X, Qu J, Miao Y, Tian L, Zhang M, Li X, Sun B, Chen L   +8 more
doaj  

Assessment of fenofibrate-methylation interactions on triglycerides using longitudinal family data

BMC Proceedings, 2018
Background Triglyceride (TG) concentrations decrease in response to fenofibrate treatment, and also are associated with DNA methylation. But how interactions between fenofibrate response and DNA methylation affect TGs remains unclear.
Jih-Chang Yu, Fang-Chi Hsu, Yen-Feng Chiu   +2 more
doaj   +1 more source